Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAX3
REST API REST API
Homo sapiens
PAX3 is differentially expressed in 217 experiments: 129 organism parts: skin, skeletal muscle, ... (127 more);, 192 disease states: normal, chronic lymphocytic leukemia, ... (190 more);, 69 cell types 257 cell lines 26 compound treatments and 76 other conditions.
Synonyms HUP2, WS1
Orthologs pax3a (Danio rerio)   pax3b (Danio rerio)   F1MTX0_BOVIN (Bos taurus)   Pax3 (Mus musculus)   F1NYH7_CHICK (Gallus gallus)   Pax3 (Rattus norvegicus)   F6SHF6_CIOIN (Ciona intestinalis)   gsb (Drosophila melanogaster)   gsb-n (Drosophila melanogaster)   prd (Drosophila melanogaster)   pax3 (Xenopus laevis)   PAX3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cell migration, DNA binding, protein binding, apoptosis, regulation of transcription, DNA-dependent, cell proliferation, positive regulation of cell proliferation, transcription from RNA polymerase II promoter, sequence-specific DNA binding, developmental pigmentation, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, sensory perception of sound, nucleus, muscle organ development, heart development, chromatin binding, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, organ morphogenesis, neural tube closure, neural crest cell migration, neural tube development, mammary gland specification, spinal cord association neuron differentiation, neuron fate commitment, sequence-specific DNA binding transcription factor activity, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term Paired_box_N, Homeobox, Pax7
UniProt Accession Q494Z4, Q494Z3, P23760
Gene-Disease Assocation CRANIOFACIAL-DEAFNESS-HAND SYNDROME; CDHS, RHABDOMYOSARCOMA 2; RMS2, WAARDENBURG SYNDROME, TYPE 1; WS1, WAARDENBURG SYNDROME, TYPE 3; WS3
Search EB-eye ENSG00000135903
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (26 experiments)

Factor Value U/D Experiments
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-20089, E-GEOD-17482
HL-60
2
E-GEOD-24147, E-GEOD-5258
MCF-7
2
E-GEOD-5823, E-GEOD-20081
PC3
2
E-MEXP-2034, E-GEOD-5258
HT1197
1
E-MTAB-37
251 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
cardiac myocyte
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-MEXP-2426
epithelial cell
1
2
E-GEOD-10797, E-GEOD-4483, E-MEXP-2034
basal cell
1
E-GEOD-3998
macrophage
1
E-GEOD-8286
immortalised T lymphocytes
1
E-GEOD-13909
63 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-15960, E-GEOD-2466, E-GEOD-1869, ... (42 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-7307
glioblastoma
2
E-GEOD-4290, E-MTAB-37
prostate cancer
2
E-MTAB-62, E-GEOD-6919
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
1
2
E-GEOD-2466, E-GEOD-6691, E-MTAB-37
lung adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-231
186 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-697, E-GEOD-5824, E-MEXP-941, E-GEOD-5339, ... (16 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-412, E-GEOD-5824, E-GEOD-697, E-MEXP-2285, E-GEOD-6431, ... (7 experiments)
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
anti-CD3 + anti-CD28
1
E-GEOD-7307
placebo
1
E-MEXP-1335
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
20 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
40
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-860, E-GEOD-2191, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-2466, E-MEXP-421, E-GEOD-22593, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540, E-MEXP-1446, E-MEXP-1741

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-GEOD-1926, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.553 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM